Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.92 USD
Change Today +0.0244 / 2.73%
Volume 4.2K
KOOL On Other Exchanges
As of 10:30 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

cesca therapeutics inc (KOOL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/10/14 - $2.04
52 Week Low
03/16/15 - $0.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cesca therapeutics inc (KOOL) Related Bloomberg News

View More Bloomberg News

cesca therapeutics inc (KOOL) Related Businessweek News

No Related Businessweek News Found

cesca therapeutics inc (KOOL) Details

Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. Its products include SurgWerks platform, a proprietary stem cell therapy point-of-care kit systems for treating vascular and orthopedic indications, which integrates various indication specific systems, such as cell harvesting, cell processing and selection, cell diagnostics, and cell delivery; and CellWerks platform for the optimal processing of targeted cells used in the treatment of oncological and hematological disorders. The company also offers MarrowXpress system, which isolates and concentrates stem cells from bone marrow; AXP System, a medical device with a disposable bag set that isolates and retrieves stem cells from umbilical cord blood; and BioArchive System, a robotic cryogenic medical device, which is used to cryopreserve and archive stem cells for future transplant and treatment. In addition, the company provides Res-Q 60 bone marrow concentrate, a centrifuge-based disposable device used for the isolation and extraction of specific stem cell populations from bone marrow; and Res-Q 60 platelet rich plasma (PRP) for the preparation of autologous PRP from a small sample of blood at the point of care. Further, it offers cell manufacturing and banking services. The company sells its products in the United States; Hong Kong, China, and other Asian countries; Europe; South America; and internationally. It was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.

95 Employees
Last Reported Date: 09/29/14
Founded in 1986

cesca therapeutics inc (KOOL) Top Compensated Officers

President and Director
Total Annual Compensation: $136.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $309.0K
Chief Biologist and Senior Vice President
Total Annual Compensation: $114.0K
Vice President of Corporate Development & Sci...
Total Annual Compensation: $240.0K
Vice President of Manufacturing, Engineering ...
Total Annual Compensation: $257.0K
Compensation as of Fiscal Year 2014.

cesca therapeutics inc (KOOL) Key Developments

Cesca Therapeutics Inc. Provides Update on Clinical Trials for Critical Limb Ischemia ("CLI") and Acute Myocardial Infarction ("AMI")

Cesca Therapeutics Inc. announced a corporate update on Cesca's clinical trial program in CLI and AMI. The company determined that in order to meet the FDA's request for additional data it would process and evaluate a number of fresh donor bone marrow samples through each individual step of the SurgWerks-CLI kit and VXP cell automation system. This process included careful characterization after bone marrow aspiration, cellular concentration and simulated delivery through the SurgWerks intramuscular needles. As requested by the FDA, the company is also adding rapid screening procedures for device cell output and sterility to ensure consistent quality in the operating room. The proposed Critical Limb Ischemia Rapid Stem Cell Therapy ("CLIRST III") study is anticipated to be a randomized double blinded placebo controlled trial to evaluate the safety and efficacy of the SurgWerks-CLI and VXP System in treating CLI patients with non-healing foot ulcers who have no further surgical/interventional options other than amputation under current standard of care guidelines. Clinical outcomes will be compared against a placebo control of the same patient population. The primary endpoint will be major amputation free survival at 12 months following enrollment and the study will be conducted across approximately 60 sites. CLI is the most severe form of Peripheral Arterial Disease ("PAD"), affecting over two million patients in the United States. It is frequently associated with chronic foot and leg ulcers, leading to approximately 200,000 amputations per year. A diagnosis of CLI statistically results in a 25% mortality rate, and a 25% amputation rate, within one year.

Cesca Therapeutics Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015 12:00 PM

Cesca Therapeutics Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015 12:00 PM. Venue: Caesars Palace, Las Vegas, Nevada, United States.

Cesca Therapeutics Inc. Receives Non-Compliance Notice From NASDAQ

On March 30, 2015, Cesca Therapeutics Inc. received a notice from the Nasdaq Listing Qualifications Department (NASDAQ) notifying the company that for 30 consecutive business days, the bid price of the company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5550(a)(2). The company has been provided with 180 calendar days (until September 28, 2015) to regain compliance. In order to regain compliance, at any time before September 28, 2015, the bid price of the company's common stock must close at a price of at least $1.00 per share for a minimum of 10 consecutive business days. The notice states that NASDAQ will provide the company with written notification when it has regained compliance. If compliance cannot be demonstrated by September 28, 2015, then NASDAQ will decide whether the company meets all applicable standards for initial listing on the Capital Market (except the bid price requirement) based on the company's most recent public filings and market information. The notice states that, if the company meets these standards, then the company may be eligible to have an additional 180 calendar day compliance period. If the company is not granted an additional 180 day calendar period, then NASDAQ will provide written notification that the company's securities will be delisted. At that time, the company may appeal the determination to delist its securities to a Listing Qualifications Panel. There are no assurances that NASDAQ will continue to grant extensions of time within which to achieve compliance.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KOOL:US $0.92 USD +0.0244

KOOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioheart Inc $0.0060 USD -0.0008
Cytori Therapeutics Inc $0.92 USD +0.0548
NeoStem Inc $2.86 USD +0.07
Nuo Therapeutics Inc $0.23 USD +0.0101
Vericel Corp $3.29 USD -0.0093
View Industry Companies

Industry Analysis


Industry Average

Valuation KOOL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CESCA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at